(NASDAQ: PEPG) Pepgen's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Pepgen's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PEPG's revenue for 2027 to be $403,436,605, with the lowest PEPG revenue forecast at $403,436,605, and the highest PEPG revenue forecast at $403,436,605. On average, 2 Wall Street analysts forecast PEPG's revenue for 2028 to be $1,151,926,307, with the lowest PEPG revenue forecast at $781,289,426, and the highest PEPG revenue forecast at $1,522,563,188.
In 2029, PEPG is forecast to generate $4,077,661,688 in revenue, with the lowest revenue forecast at $4,007,798,276 and the highest revenue forecast at $4,147,525,100.